HC Wainwright Has Bullish Outlook for SGMO FY2028 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Equities researchers at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for Sangamo Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn $0.64 per share for the year, up from their previous estimate of $0.63. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.51) per share.

Other equities analysts have also issued reports about the stock. Barclays lifted their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday. StockNews.com raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday.

Sangamo Therapeutics Trading Down 11.9 %

Shares of SGMO stock opened at $2.15 on Friday. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The business’s 50 day moving average is $1.30 and its two-hundred day moving average is $0.85.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Meritage Portfolio Management increased its holdings in Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its stake in Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 23,650 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 38,850 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after buying an additional 57,125 shares in the last quarter. Finally, Golden State Equity Partners raised its holdings in shares of Sangamo Therapeutics by 35.2% in the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 69,368 shares during the last quarter. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.